Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report




Abstract is missing (Short communication)


Download data is not yet available.


Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci 2017; 18: 2532. DOI:

Wang M, Li F, Wang X, Wang X, Wang R, Yang Y, et al. Features and risk factors for paraneoplastic autoimmune multiorgan syndrome in 145 Chinese patients. Acta Derm Venereol 2020; 100: adv00312. DOI:

Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol 2019; 80: 1544-1549. DOI:

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29: 2062-2068. DOI:

Takahashi H, Kouno M, Nagao K, Wada N, Hata T, Nishimoto S, et al. Desmoglein 3-specific CD4+ T cells induce pemphigus vulgaris and interface dermatitis in mice. J Clin Invest 2011; 121: 3677-3688. DOI:

McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021; 398: 803-816. DOI:

Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood 2014; 123: 3832-3842. DOI:

Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. JAMA Ophthalmol 2018; 136: 1420-1422. DOI:

James H, Paley GL, Brasington R, Custer PL, Margolis TP, Paley MA. Tofacitinib for refractory ocular mucous membrane pemphigoid. Am J Ophthalmol Case Rep 2021; 22: 101104. DOI:

Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med 2014; 370: 1820-1828. DOI:

Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, et al. Salvage therapy with low-dose ruxolitinib leads to a significant improvement in bronchiolitis obliterans syndrome in patients with cGVHD after allogeneic hematopoietic stem cell transplantation. Front Pharmacol 2021; 12: 668825. DOI:

Kaurinovic M, Delli K, Jonk AE, Biswana A, Hazenberg CLE, Choi G, et al. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic graft-versus-host disease and oral involvement. Clin Oral Investig 2022; 26: 4209-4216. DOI:

Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561. DOI:

Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, et al. Efficiency and toxicity of ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol 2021; 12: 673636. DOI:

Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 2018; 93: 339-347. DOI:



How to Cite

Fan, B., & Wang, M. (2022). Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report. Acta Dermato-Venereologica, 102, adv00732.



Short Communication